New Hampshire Cannabis Market Analysis: Four Certificates, Seven Doors, $10/Gram

New Hampshire's therapeutic cannabis program enrolled 16,846 patients as of June 2025 — up 14.6% in a single year, its strongest growth since the 2018–2020 expansion phase — served by three nonprofit operators holding four statutory Alternative Treatment Center certificates across seven dispensing locations. RSA 126-X:7 caps the program explicitly: no more than four ATC certificates may exist at one time. Roughly 8.5% of the state's modeled cannabis-consuming population holds a card — well below South Dakota's ~16%, closer to North Dakota's capped ~9.5% and Iowa's ~4%. Flower across all three operators converges to a median advertised price of $10.00 per gram, with unusually little variation between them. New Hampshire isn't an exception to this series' pattern of capped markets — it's a another example consistent with it, via a different statutory instrument than Iowa's, North Dakota's, or Louisiana's.

Market Overview

New Hampshire's Therapeutic Cannabis Program operates under RSA 126-X. Growth has been steady since 2016, with one recent acceleration:

The state's own 2022 report is internally inconsistent — its historical bar chart mislabels that year's total as 13,364, while the report's headline figure and county-level breakdown both sum to 13,634, the number used above. The 2025 increase is the program's largest annual percentage gain since 2020, narrowly exceeding 2021's 14.5%.

The likely driver: two new qualifying pathways took effect in fall 2024 — generalized anxiety disorder (HB 1349, September) and a broad catch-all for "any debilitating or terminal medical condition" left to provider discretion for patients 21+ (HB 1278, October). The 2025 report records 906 patients under the anxiety pathway and 96 under the catch-all; since patients can hold multiple qualifying conditions, those figures aren't a clean count of newly enrolled patients, but the timing lines up closely enough to be the leading explanation.

Key metrics (June 30, 2025): 16,846 active patients (16,838 adult, 8 minor); 1,435 caregivers; 1,537 certifying providers (861 physicians, 537 APRNs, 133 PAs, 5 naturopathic doctors, 1 podiatrist — the last two newly authorized by SB 357); top conditions are chronic pain (9,045), PTSD (3,604), and severe pain (2,022). Home cultivation is not permitted in any form — GraniteLeaf's patients list its absence as a top complaint, and Sanctuary and Temescal both recommend allowing it, alongside eliminating the nonprofit ownership requirement that governs all three operators.

The Statutory Structure

New Hampshire caps its market by certificate, not by store count. RSA 126-X:7, III states it without qualification: "No more than 4 alternative treatment centers shall hold valid registration certificates at one time." The same section requires the state to accept new applications if the count ever falls below four, but the ceiling itself is absolute.

Four certificates sit with three operators — Temescal Wellness appears to hold two, accounting for its three locations (Dover, Lebanon, Keene) against one certificate apiece for GraniteLeaf (Chichester) and Sanctuary (Plymouth). A separate provision allows DHHS to authorize each ATC to establish a second dispensing-only location within its own geographic area, if the department determines additional access is necessary — the likely mechanism turning four certificates into seven physical doors: Chichester+Merrimack, Plymouth+Conway, and Temescal's two certificates covering Dover, Lebanon, and Keene between them.

It's a softer instrument than Iowa's flat store cap or North Dakota's flat producer-and-store cap — a certificate can still expand into a second door — but it's a real numeric ceiling, not an emergent outcome of an open market. Layered on top is the nonprofit mandate itself, which Sanctuary and Temescal are both on record asking the state to eliminate.

New Hampshire's density sits between North Dakota's harder store-count ceiling and Iowa's near-total absence of retail — roughly where a certificate cap with a partial expansion allowance should land.

Enrollment Share

At the framework's 18% participation baseline, New Hampshire's ~1.10 million adults 21+ imply roughly 198,000 modeled consumers. Against 16,846 patients, that's a modeled enrollment share of ~8.5% — not an observed program statistic, but a framework estimate.

That figure is mediocre and consistent with New Hampshire's peers among capped markets, not an outlier. South Dakota, this series' clearest open-market case, runs roughly 15–16%; New Hampshire's 8.5% is barely half that, sitting between North Dakota's capped ~9.5% and Iowa's ~4%. The four-certificate ceiling is associated with an enrollment rate in the same range as North Dakota's harder store-count ceiling.

The Pricing Audit

A single-pass menu audit conducted in July 2026, covering six of the state's seven locations (Conway's Sanctuary menu wasn't included), recorded 90 flower listings, unpublished as a standalone dataset and not independently verified — a documented spot-check rather than a reproducible sample. It also pools Temescal's three locations against GraniteLeaf's two and Sanctuary's one, which could overweight Temescal's specific pricing in the pooled figures below.

• Standard eighths (81 of 90): mean $10.07/g, median $10.00/g, range $9.43–$11.43/g — roughly 20% spread floor to ceiling.
• A $17.50/eighth tier ($5.00/g) appears only at Temescal locations, at a similar reported potency range to the standard tier — it does not appear to be differentiated by advertised potency, suggesting a discount or inventory-pricing tier rather than a distinct quality tier.
• GraniteLeaf's Chichester half-ounce ($89, $6.36/g) is the only quantity-based discount found in the audit.

The tightness of the standard tier is still notable: North Dakota's actual two-producer duopoly showed more price variation across its menus than New Hampshire's three separately-owned operators show here. A four-certificate cap plus mandatory nonprofit ownership may remove enough competitive pressure to produce that, though vertical integration, compliance costs, and production economics are plausible contributing factors this audit can't isolate. Patient complaints point the same direction without confirming a cause — Sanctuary's patients cite "lack of high potency strains," GraniteLeaf's cite inconsistent availability.

These are advertised list prices; each ATC also runs an affordability program (10–35% off) covering 17.3% of GraniteLeaf's patients, 25% of Sanctuary's, and 55% of Temescal-Dover's. Back-solving GraniteLeaf's flat 10% recurring discount — $465,608 in discount value from its ongoing affordability programs, excluding a separate, larger figure that includes promotional sales events — implies ~$4.66 million in gross pre-discount purchase value among its 1,082 enrolled patients (roughly $4.19 million actually paid) — a subgroup of low-income, veteran, and senior patients specifically, not representative of the general patient base. Sanctuary's discount is capped at 30–35% off the first $100 spent every 10 days, so its $254,948 figure is a floor on spend, not a proportional estimate. No ATC publishes aggregate sales, so a true blended transaction price isn't derivable from what's disclosed.

Home Cultivation

Not permitted, for patients or caregivers, in any form — a complete prohibition, unlike South Dakota's limited allowance. Both GraniteLeaf's patients and two of the three ATCs have asked the department to change that.

The framework's cost accounting of home cultivation calls growing "economically neutral at best" against a $6.50/g national baseline — average consumption nets about $2.11/hour of labor once the grow space itself is priced in. At New Hampshire's $10.07/g, that math improves: recomputing at the same 1.0 g/day baseline and the source article's own 200-hour labor assumption, growing nets roughly $1,726/year over buying — about $8.63/hour, roughly four times the national-baseline rate. Adoption would likely stay low regardless (fewer than 5% of consumers grow even where fully legal, for reasons that aren't about money), but at this price level the ban is plausibly costing patients real savings in a way it wouldn't in a cheaper market.

Volume Capture

The five-state per-patient spend band used elsewhere in this series ($2,100–2,650/year, averaging $2,375) reflects patients converging on roughly a fixed monthly budget regardless of local price. At New Hampshire's $10.07/g, ~$200/month buys about 20 grams — roughly 65% of the framework's 1.0 g/day baseline. Combined with the 8.5% enrollment share, that's a scenario estimate of ~5–6% modeled volume capture. The framework's standard dollar-based approach — $40.0M modeled spend against a ~$397M TAM — implies ~10% modeled dollar capture instead, which is the weaker number to lead with here: it assumes a national-pattern budget without accounting for what that budget buys at New Hampshire's price level. Both figures are scenario estimates under the framework's assumptions, not observed sales or consumption data, and neither isolates price as the sole driver — the model combines below-average enrollment with reduced volume per patient, and both inputs contribute.

The Bottom Line

New Hampshire is a fourth entry in this series' catalog of statutorily capped markets, not an exception to it. RSA 126-X:7 limits the program to four ATC certificates, held by three nonprofit operators each permitted one additional dispensing location, producing seven doors for roughly 1.1 million adults. That structure — plus a nonprofit mandate two of the three operators want removed — is associated with a modeled enrollment share (8.5%) closer to North Dakota's harder cap (~9.5%) than to South Dakota's open market (~15–16%), and flower pricing ($10.00/g median) tighter than North Dakota's actual duopoly manages.

This doesn't prove the certificate cap is the sole cause of the pricing pattern — vertical integration and production economics remain plausible contributors this analysis can't fully separate out. What it shows is a market under a real statutory ceiling, producing outcomes consistent with this series' other capped states, via a mechanism — certificates rather than stores — none of Iowa, North Dakota, or Louisiana use. Whether continued enrollment growth pushes existing certificate-holders toward their second-location allowance, or builds pressure to revisit the four-certificate ceiling itself, is the open question ahead.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.